Overview

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and pharmacokinetics of RC98 for injeciton in subjects with advanced malignant solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
RemeGen
RemeGen Co., Ltd.